Risk Of Developing Liver Cancer After HCV Treatment

Friday, May 26, 2017

Push for generic drugs in India

Push for generic drugs in India
Even as India’s National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of 31 more drug formulations, in yet another crackdown on prices, India's premier policy formulating agency Niti Aayog has proposed a change in the manner the government should identify drugs to be brought under price control....

While the Indian government is strongly backing generic drugs, a report from an international research team has found that the use of the generic versions of direct-acting antiviral (DAA) drugs that are available in India to treat hepatitis C virus (HCV) infection are not only cost effective, but actually save lifetime costs for treating infected patients in India....

The report states that the upfront costs of DAA are offset by the avoidance of costs incurred to treat late-stage disease....
Continue reading....

Related Articles On This Blog
HCV generics

No comments:

Post a Comment